AMENDMENTS TO THE CLAIMS

1-26. (Cancelled)

27. (Previously presented) A method for producing an anti-tumor response in a mammalian subject, said method comprising

activating autologous immune cells by co-cultivating in vitro a plurality of dendritic cell/tumor cell hybrids with immune cells from a mammalian subject; and

administering to said subject the activated autologous immune cells.

28. (Previously presented) A method for producing anti-tumor response in a mammalian subject, said method comprising

activating autologous immune cells by co-cultivating in vitro a dendritic cell/tumor cell hybridoma with immune cells from a mammalian subject; and

administering to said subject the activated autologous immune cells.

29. (Original) The method of claim 27 wherein said cells are administered by injection or infusion.

30. (Original) The method of claim 28 wherein said cells are administered by injection or infusion.

31. (Original) The method of claim 29 wherein said injection is carried out parenterally.

32. (Original) The method of claim 30 wherein said injection is carried out parenterally.

33. (New) The method of claim 27 wherein the anti-tumor response is induced in vitro against a specific tumor.

34. (New) The method of claim 28 wherein the anti-tumor response is induced in vitro against a specific tumor.

35. (New) The method of claim 27 wherein the plurality of hybrids is further induced to express dendritic cell characteristics before using said hybrids for co-cultivation.

36. (New) The method of claim 28 wherein the hybridoma is further induced to express dendritic cell characteristics before using said hybridoma for co-cultivation.

37. (New) The method of claim 35 wherein said dendritic cell characteristics are selected from the group consisting of dendritic cell morphology, dendritic cell surface markers or dendritic cell activation markers and immune cell activation properties in vitro.

38. (New) The method of claim 36 wherein said dendritic cell characteristics are selected from the group consisting of dendritic cell morphology, dendritic cell surface markers or dendritic cell activation markers and immune cell activation properties in vitro.

39. (New) The method of claim 35 wherein said induction is performed using GM-CSF.

40. (New) The method of claim 36 wherein said induction is performed using GM-CSF.

41. (New) The method of claim 27 wherein the plurality of hybrids is treated to prevent proliferation before using said hybrids for co-cultivation.

42. (New) The method of claim 28 wherein the hybridoma is treated to prevent proliferation before using said hybridoma for co-cultivation.

43. (New) The method of claim 41 wherein said treatment occurs by irradiation.

44. (New) The method of claim 42 wherein said treatment occurs by irradiation.

45. (New) The method of claim 27 wherein said dendritic cell is an isolated dendritic cell.

46. (New) The method of claim 28 wherein said dendritic cell is an isolated dendritic cell.

47. (New) The method of claim 27 wherein said dendritic cell is a dendritic cell progenitor

48. (New) The method of claim 28 wherein said dendritic cell is a dendritic cell progenitor.

49. (New) The method of claim 27 wherein said dendritic cell is derived from bone marrow.

50. (New) The method of claim 28 wherein said dendritic cell is derived from bone marrow.

51. (New) The method of claim 27 wherein said dendritic cell is myeloid origin.

52. (New) The method of claim 28 wherein said dendritic cell is myeloid origin.

53. (New) The method of claim 27 wherein said dendritic cell is lymphoid origin.

54. (New) The method of claim 28 wherein said dendritic cell is lymphoid origin.